Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 02 2020
accepted: 16 07 2020
pubmed: 11 8 2020
medline: 22 5 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

The CYP2B6 gene is highly polymorphic and its activity shows wide interindividual variability. However, substantial variability in CYP2B6 activity remains unexplained by the known CYP2B6 genetic variations. Circulating, cell-free micro RNAs (miRNAs) may serve as biomarkers of hepatic enzyme activity. CYP2B6 activity in 72 healthy volunteers was determined using the disposition of efavirenz as a probe drug. Circulating miRNA expression was quantified from baseline plasma samples. A linear model consisting of the effects of miRNA expression, genotype-determined metabolizer status, and demographic information was developed to predict CYP2B6 activity. Expression of 2,510 miRNAs were quantified out of which 7 miRNAs, together with the CYP2B6-genotypic metabolizer status and demographics, was shown to be predictive markers for CYP2B6 activity. The reproducibility of the model was evaluated by cross-validation. The average Pearson's correlation (R) between the predicted and observed maximum plasma concentration (C

Identifiants

pubmed: 32772362
doi: 10.1002/cpt.2018
pmc: PMC9007394
mid: NIHMS1683365
doi:

Substances chimiques

Alkynes 0
Anti-HIV Agents 0
Benzoxazines 0
Biomarkers 0
Cyclopropanes 0
MicroRNAs 0
CYP2B6 protein, human EC 1.14.14.1
Cytochrome P-450 CYP2B6 EC 1.14.14.1
efavirenz JE6H2O27P8

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

485-493

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM078501
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121707
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM131812
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008425
Pays : United States

Informations de copyright

© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Pharmacol Ther. 2012 Mar;91(3):475-82
pubmed: 22318618
Pharmacogenet Genomics. 2007 Jun;17(6):431-45
pubmed: 17502835
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Clin Pharmacol Ther. 2007 May;81(5):719-28
pubmed: 17329992
PLoS One. 2013 Sep 13;8(9):e74471
pubmed: 24058572
J Pharmacol Exp Ther. 2008 Apr;325(1):284-92
pubmed: 18171905
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
pubmed: 12011421
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27799204
Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6
pubmed: 9878993
Biochim Biophys Acta. 2016 Sep;1859(9):1238-1244
pubmed: 27085140
Pharmacogenomics J. 2014 Apr;14(2):151-9
pubmed: 23629159
AIDS. 2001 Jan 5;15(1):71-5
pubmed: 11192870
J Pharmacol Exp Ther. 2003 Jul;306(1):287-300
pubmed: 12676886
Clin Pharmacol Ther. 2019 Oct;106(4):726-733
pubmed: 31006110
Clin Pharmacol Ther. 2018 Mar;103(3):399-401
pubmed: 29134625
Clin Pharmacol Ther. 2019 Jan;105(1):29-32
pubmed: 30536702
Drug Metab Dispos. 2003 May;31(5):620-30
pubmed: 12695351
Pharmacogenomics. 2007 Jun;8(6):547-58
pubmed: 17559344
Pharmacogenet Genomics. 2005 Dec;15(12):861-73
pubmed: 16272958
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Pharmacol Ther. 2011 Sep;131(3):330-7
pubmed: 21565218
J Biol Chem. 2003 Apr 18;278(16):14146-52
pubmed: 12571232
J Biol Chem. 1999 Mar 5;274(10):6043-6
pubmed: 10037683
Clin Pharmacol Ther. 2018 Jul;104(1):130-138
pubmed: 28960269
Front Genet. 2013 Mar 05;4:24
pubmed: 23467454
Curr Drug Metab. 2008 Sep;9(7):598-610
pubmed: 18781911
Drug Metab Dispos. 2012 Apr;40(4):726-33
pubmed: 22232426
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Joseph Ipe (J)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Rudong Li (R)

Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Ingrid F Metzger (IF)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Jessica Bo Li Lu (J)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Brandon T Gufford (BT)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Zeruesenay Desta (Z)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Yunlong Liu (Y)

Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Todd C Skaar (TC)

Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH